BHCM
TYRA icon

Brevan Howard Capital Management’s Tyra Biosciences TYRA Stock Holding History

Brevan Howard Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.46M Buy
+38,606
New +$1.25M 0.01% 712
2025
Q4 		– Sell
-31,101
Closed -$435K – 2290
2025
Q3 		$435K Sell
31,101
-5,493
-15% -$62.6K ﹤0.01% 1358
2025
Q2 		$350K Sell
36,594
-9,777
-21% -$92.9K ﹤0.01% 1496
2025
Q1 		$431K Buy
+46,371
New +$600K ﹤0.01% 758

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Brevan Howard Capital Management's TYRA Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Tyra Biosciences (TYRA) in Q1 2026: 38,606 shares worth $1.46M. The stake represents 0.01% of the portfolio and ranks #712 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in TYRA as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in TYRA in Q1 2025 and has held it in 4 quarters since. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Brevan Howard Capital Management held 38,606 shares of Tyra Biosciences worth $1.46M as of Q1 2026.
  • Tyra Biosciences was a new Brevan Howard Capital Management position in Q1 2026.
  • Tyra Biosciences made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #712 holding.
  • Brevan Howard Capital Management first reported a position in Tyra Biosciences in Q1 2025 and has held it in 4 quarters since.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.